<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1186/s42155-018-0008-2</dc:identifier><dc:language>eng</dc:language><dc:creator>Mayoral Campos, Victoria</dc:creator><dc:creator>Guirola Órtiz, José Andrés</dc:creator><dc:creator>Tejero Juste, Carlos</dc:creator><dc:creator>Gimeno Peribáñez, María José</dc:creator><dc:creator>Serrano, Carolina</dc:creator><dc:creator>Pérez Lázaro, Cristina</dc:creator><dc:creator>de Blas Giral, Ignacio</dc:creator><dc:creator>de Gregorio Ariza, Miguel Ángel</dc:creator><dc:title>Carotid artery stenting in a single center, single operator, single type of device and 15 years of follow-up</dc:title><dc:identifier>ART-2018-106804</dc:identifier><dc:description>Background: Revascularization with carotid stent (CAS) is considered the therapeutic alternative to endarterectomy (CEA). However, its role compared to CEA remains questioned, mainly due of the heterogeneity of long-term results. The objective of this study was to report the efficacy and durability of CAS in terms of stroke prevention in a “real world experience”.
Method: This was a single-center retrospective analysis of 344 patients treated with CAS between January 2001 and December 2015.
The primary outcome of the trial was stroke, myocardial infarction, or death during a periprocedural period or
any stroke event over a 15-year follow-up. The secondary aim was to identify risk factors for 30-day complications, long-term neurological complications, and intra-stent restenosis.
Results: The primary composite end point (any stroke, myocardial infarction, or death during the periprocedural period) was 2.3%. The use of an EPD was protective against major complications.
Long-term follow-up was achieved in 294 patients (85,5%) with a median of 50 months (range 0-155 months). Fifty-six (16,3%) died within this period, most commonly of nonvascular causes (4 patients had stroke-related deaths). During the follow-up period, 8 strokes and 3 TIAs were diagnosed (3.2%).
ISR determined by sequential ultrasound was assessed in 4.4% of the patients and remained asymptomatic in all but 2 patients (0.6%). All patients with restenosis underwent revascularization with balloon angioplasty.
Conclusion: The long-term follow-up results of our study validate CAS as a safe and durable procedure with which to prevent ipsilateral stroke, with an acceptable rate of restenosis, recurrence and mortality.</dc:description><dc:date>2018</dc:date><dc:source>http://zaguan.unizar.es/record/71222</dc:source><dc:doi>10.1186/s42155-018-0008-2</dc:doi><dc:identifier>http://zaguan.unizar.es/record/71222</dc:identifier><dc:identifier>oai:zaguan.unizar.es:71222</dc:identifier><dc:identifier.citation>CVIR endovascular 1, 3 (2018), [8 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>